Overview

• US fertility and birth control device maker's Q1 sales rose 24.5% yr/yr, led by FemBloc

• Company posted net income after prior-year loss, aided by gains in fair value of instruments

• Femasys advanced commercialization and expanded international partnerships during the quarter

Outlook

• Company expects current cash resources to fund operations into the third quarter of 2026

Result Drivers

• FEMBLOC SALES - Co said Q1 sales growth was primarily due to sales of FemBloc

• COMMERCIALIZATION EFFORTS - Co advanced commercial adoption of FemaSeed Complete and expanded provider awareness and partnerships

• LOWER R&D EXPENSES - Co reported decreased R&D expenses due to transition of products into inventory and lower development costs

Company press release: ID:nGNX5SDnWR

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Femasys Inc is $4.50, about 902% above its May 7 closing price of $0.45

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.